Clinical trial · Interventional
Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The clinical trail of Cinobufacini injection combined with Oxaliplatin regimen on gastrointestine carcinoma.This trail is randomized controled.Patients are diagnosed gastrointestinal cancer based on pathology or cell biology.They are randomized into 2 groups:both groups receive Oxaliplatin regimen.The treatment group receives Cinobufotalin 20ml mixed with 5% Glucose injection 500ml from the first day of chemotherapy until seven days in addition to the chemotherapy.The control group only receive the same chemotherapy with the treatment group.Both group have the same adjuvant therapy.Mainly to study of oxaliplatin into Cinobufacini injection leads to the influence of the peripheral nerve toxicity.Clinical evaluation includes neural electrophysiological test,chemotherapy drug toxicities,quality of life(QOL),etc.Blood biochemistry tests mainly include inflammatory cytokines,peroxidase reaction,immune cell number ratio and stress hormone,etc.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Neoplasms | Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy | Drug | Chemotherapy | ALIAS |
| Cinobufacini injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cinobufacini injection
- description
- Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day. Duration:6 chemotherapy cycles.
- interventionNames
- Drug: Cinobufacini injection
- Drug: chemotherapy
- type
- OTHER
- label
- Control group
- description
- Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
- interventionNames
- Drug: chemotherapy
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age:18-70 * male and female * signed the informed consent form. * Diagnosis:Gastrointestinal cancer diagnosed by imaging,cell and pathology report. * Eastern Cooperative oncology Group(ECOG)O-2,life expectancy more than 3 months. * Indication for Chemotherapy,no contraindication. * First time chemotherapy or at least 6 months after last chemotherapy and radiotherapy. * At least 8 weeks after last biotherapy. * Surgery:had not received transplantation surgery,at least 2 weeks after last major surgery. Exclusion Criteria: * Chemotherapy is contraindicated. * Have the primary disease can cause the neuropathy. * A history of other malignant tumor in recent 5 years. * Less than 6 months after last chemotherapy or radiotherapy. * Less than 8 weeks after last biotherapy. * Cinobufotalin allergy. * Had received transplantation surgery,less than 2 weeks after last major surgery. * Other researchers think is not suitable for this clinical trail.
References
Publications (0)
Data not yet available